ABBV Textbook Cup&Handle Pattern. Confirmation of uptrend?A textbook example of cup&handle pattern forming on ABBV, I think its interesting to dig deeper into the company, as its a defensive stock for just the conditions at the current moment.
4AB trade ideas
ABBV Bearish Rising WedgeHealthcare has been a safe haven for big institutions, with oil hurting this may be a later breakdown following the market
AbbVie (ABBV) ... Call a Medic please What Happens when Bearish Harmonic Crabs and Cyphers Meet ??
Of all the major 11 S&P sub-sectors, the Health care (XLV) seems the most technically vunerable. (see insert)
Herein we have a well formed Gartley pattern waiting to roll over.
Drilling down to the major holdings of this index, AbbVie Inc. (ABBV) also looks the most vulnerable and ready to roll over,
I see two cypher patterns and one crab terminating. That said, latter is under-formed and I would like to see this crab in waiting terminate in the low $170's to short or exit a long position.
Also the Cypher patterns sometimes turn into Sharks... another eventuality that may happen.
Additionally my momentum indicator in the lower panel needs to decisively roll over.
So we need more pieces in place.
Lots of volatility this week, the Fed, Oil and probably the beginning of holiday constricted trade,
I will advise of a position taken.
Not Investment advice, do your own due diligence and respect overall broad markets and trends,
S.
If ABBV chooses to decline, we are ready.AbbVie - 30d expiry - We look to Sell a break of 132.58 (stop at 137.03)
133 continues to hold back the bears.
132.75 has been pivotal.
Posted a Double Bottom formation.
A break of the recent low at 132.74 should result in a further move lower.
Our profit targets will be 121.01 and 117.01
Resistance: 154 / 157 / 160
Support: 147 / 142 / 137
Disclaimer – Saxo Bank Group.
Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
ABBV | Bull Flag Formation | LONGNYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie shortAbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutics areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience and also offers treatments for parkinson's, alzheimer's disease.
I guess its stock can be down to $142 and below.
My trade levels
Entry: $158.57
Take profit: $142.54
Stop loss: $164.62
Risk/reward: 2.65
ABBV Inverse Head and Shoulders Bullish - Santa rally Skew Inverse Head And Shoulders with a target of $174.65.
We do see bullish signals momentum wise where 7>21 >200.
Bullish
Let's just hope a bull market does kick in here as we enter the Christmas season with a Santa Rally.
IS $ABBV ready to come up on the right side of its base?Notes:
* Strong up trend on all time frames
* Great earnings track record
* Basing for the past ~8 months
* Now looking to come up on the right side of its base
* Printed a pocket pivot in the last session, indicating institutional buying
* Offering an early entry relative to its 50 day line
Technicals:
Sector: Healthcare - Drug Manufacturers - General
Relative Strength vs. Sector: 6.46
Relative Strength vs. SP500: 2.33
U/D Ratio: 1.4
Base Depth: 28.76%
Distance from breakout buy point: -12.22%
Volume 18.24% above its 15 day avg.
Trade Idea:
* You can enter now as the price is coming off of its 50 day line
* If you're looking for a better entry you can look for one around the ~147 area as that should hold as support moving forward
* If you're looking for a safer entry you can wait for a break and close above the ~152.5 area as that is the immediate resistance coming up
* A daily close below the ~147 area would negate the bullish outlook.
$ABBV with a Neutral outlook following its earnings #Stocks The PEAD projected a Neutral outlook for $ABBV after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 100%.
ABBV is bull flaggingFrom B to C is not quite 61.8% retrace from flagpole high, but close enough.. B to C forms a nice bull flag, a continuation of primary trend. The breakout should occur at the mid line of the longer term upward channel. A 1.27 extension should give a target of 187 around Feb. 13 2023.
Healthcare (in addition to energy) is one of few sectors currently showing promise. Earnings on 10/28/22, Friday.
ABBV: some upside potential?A price action above 138.00 supports a bullish trend direction.
Crossing below this level wil negate the bullish stance.
Consolidation price range between 140.00 to 144.00
Crossing above this level will assist the bullish trend to target 149.00
Crossing below 140.00 will be the first sign of pending weakness.
ABBVmany Health Technologies went down .. Is ABBV lagging behind?
the triangle makes sense, the trendline makes sense and the volumes too
ABBV back above EMA200Great reversal af double bottom support.
Reversed back above EMA200 making a short term golden cross.
Waterfall on AbbVie. ABBVBetting on a further crash in AbbVie stock price. That huge candle preempts formal volatility switch. Fractally, hard to tell from this picture, possibly a start of a C in a WXY pattern.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
RectangleNeutral pattern.
ABBV pays a good yield and is still above the .382.
Possible inverse H&S inside the rectangle. If so the neckline in orange. If ABBV broke this line, a 100% move would take it to the top of the rectangle, or the resistance line.
EPS (FWD)
13.86
PE (FWD)
10.13
Div Rate (FWD)
$5.64
Yield (FWD)
4.02%
Short Interest
0.64%
Market Cap
$250.66B
No recommendation
AbbVie. Waiting for an exit from uptrendAbbVie Inc.
Idea: Long
Horizon: 1-2 months
Target: $145
Entry range: $143-145
Stop order: $141
Technical analysis
The share price has formed a short-term uptrend. If the local resistance level is broken through, there is a potential to move higher. Idea to increase the stock with the target of $145.
Fundamental factor
AbbVie is an American biopharmaceutical company founded in 2013 by a spinoff from Abbott Laboratories. One of the largest pharmaceutical companies in the world. Healthcare is a classic defensive sector in times of stock market turbulence. Given the high likelihood of continued serious tightening of monetary policy by the Fed, investors are shifting funds from interest-rate-dependent sectors to more stable ones. AbbVie's broadly diversified portfolio of drugs and products makes it one of the best candidates for this strategy.
ABBV to 147?I am really liking @abbv right now. That's a nice support level and for the size of that candle it did not have a strong volume. In my opinion @ABBV is consolidating. It's creating a compression on that gray area. ORRRRR is creating and inverted Head And Shoulder? Green line
ANY THOUGHTS?
"This is only my personal opinion. I am not a trading/finance adviser"
Short $ABBV from 144.25$ABBV at top of channel, but still trending down. RSI and MACD starting to round and point downwards. I hope to catch 144.25 on a positive day for markets this week.
Entry: 144.25
TP: 123,62
SL: 150,6
Falling Wedge on the dailyOur AbbVie is trying to break out of the "Falling Wedge" pattern but is having a hard time.
Despite the pattern resistance being broken, momentum is weakening (MACD).
In addition, the volume is nearly average.
It is the opposite of what we want to see when we expect a breakout from a 222-day pattern.
It is probably due to bearish market sentiment.
Given the situation, I have marked the two possible scenarios on the graph.
1. Scenario: overall market turns bullish.
In this case, there is a chance for continuation with a target price of 151.72.
2. Scenario: market keeps dipping.
I expect a false outbreak. In this case, we could easily visit the 131.18 level.
Support: 141.88, 141, 137.55, 131.18
Resistance: 147.4, 150.78, 151.87
